Granted Patent
B1
US 7,211,582 · App. 09/447,218 · Granted May 1, 2007
Methods for treating urticaria using descarboethoxyloratadine
Assignee:
Sepracor Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.
Claims (2)
1. A method of treating urticaria in a human comprising orally administering to a human a therapeutically effective amount of descarboethoxyloratadine (DCL) or a pharmaceutically acceptable salt thereof, wherein the therapeutically effective amount is from 0.1 to 5.0 mg per day.
2. The method of claim 1 wherein the amount of said descarboethoxyloratadine (DCL) is administered together with a pharmaceutically acceptable carrier.
Assignments (1)
CHANGE OF NAME
Recorded Jan 25, 2011
From: SEPRACOR INC.
To: SUNOVION PHARMACEUTICALS INC.
Reel/Frame 025689/0743 →
Continuity (3)